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Abstract
Aeromonas salmonicida subsp. salmonicida is the etiological agent of furunculosis and a
major fish health problem in salmonid aquaculture worldwide. Injection vaccination with
commercial mineral oil-adjuvanted bacterin vaccines has been partly successful in prevent-
ing the disease but in Danish rainbow trout (Oncorhynchus mykiss, Walbaum) aquaculture
furunculosis outbreaks still occur. In this study we tested the efficacy of experimental subunit
vaccines against A. salmonicida infection in rainbow trout. We utilized in silico screening of
the proteome of A. salmonicida subsp. salmonicida strain A449 and identified potential pro-
tective protein antigens that were tested by in vivo challenge trial. A total of 14 proteins were
recombinantly expressed in Escherichia coli and prepared in 3 different subunit vaccine
combinations to immunize 3 groups of rainbow trout by intraperitoneal (i.p.) injection. The
fish were exposed to virulent A. salmonicida 7 weeks after immunization. To assess the effi-
cacy of the subunit vaccines we evaluated the immune response in fish after immunization
and challenge infection by measuring the antibody levels and monitoring the survival of fish
in different groups. The survival of fish at 3 weeks after challenge infection showed that all 3
groups of fish immunized with 3 different protein combinations exhibited significantly lower
mortalities (17–30%) compared to the control groups (48% and 56%). The ELISA results
revealed significantly elevated antibody levels in fish against several protein antigens, which
in some cases were positively correlated to the survival.
Introduction
Aeromonas salmonicida subsp. salmonicida (hereafter AS) is the causative agent of typical
furunculosis in aquacultured salmonid fish. Furunculosis causes bacterial septicemia that leads
to significant economic losses due to fish morbidity and mortality [1].
Vaccination of salmonids against furunculosis is generally applied with injection vaccines
containing formalin-killed AS bacteria combined with mineral oil adjuvant. These vaccines
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provide efficient protection and induce long-lasting immunity against the bacterium under
certain conditions [2]. However the prophylactic effect of the vaccines in Danish rainbow
trout is suboptimal under field conditions and the maricultured fish still experience furunculo-
sis outbreaks during the warmer summer months [3, 4]. Furthermore, adverse side-effects like
intra-abdominal lesions, retarded growth, pigmentation and autoimmunity [2, 5–9] have been
associated with vaccine administration. Consequently, research for developing more effective
furunculosis vaccines with fewer side-effects is ongoing.
The bacterium of AS, first described in 1894 [10] is one of the most important and exten-
sively studied fish pathogens. Important virulence factors identified in AS comprise the A-
layer protein VapA [11–14], several iron-regulated outer membrane proteins (IROMPs) [15–
19], extracellular protein complexes including serine protease AspA and lipase CGAT with
LPS [20–23] and the type three secretion system T3SS [24] consisting of effector and structural
proteins essential for AS virulence [25–27]. The potential of these pathogenic and virulence
factors as vaccine candidates has been investigated in challenge trials previously [15, 28–36].
In this study we applied an in silico approach to select potential vaccine candidates for
experimental furunculosis vaccines and selected 14 proteins for in vivo trial. The proteins were
recombinantly expressed in E. coli and prepared in 3 different vaccine combinations to immu-
nize groups of rainbow trout by intraperitoneal (i.p.) injection. The vaccine efficacy was
assessed by infection trial and by measuring the antibody reactivity in immunized fish on
grounds that the antibody response has in several studies confirmed to be closely correlated to
protection [14, 37, 38].
Materials and methods
Rationale selection
The functionality and domain classification of 14 proteins (Table 1) was conducted by Inter-
Pro [39]. The subcellular localization of the individual proteins was predicted by the CELLO
and pSORTb predictor [40, 41] that provide an output with reliability score for each location
of each protein. Commonly, protective B-cell protein antigens are located in the outer mem-
brane and extracellular environment, hence these predicted subcellular locations were targets
for selection [42, 43]. The conservation study was done by local sequence alignment (Smith–
Waterman algorithm) [44] based on the amino-acid sequence of the protein antigens tested
for conservation across the public available NCBI chromosome data. The pair-wise alignment
values (% similarity and % coverage) were calculated and the most similar protein to a given
genome was selected and classified as homologous if the % similarity was >75% on at least
75% of the total protein length (% coverage). Protein conservation correlates with an increased
probability of success, due to the ability to elicit protection across different bacterial strains
[45]. Therefore, we performed a conservation analysis of the initially selected A. salmonicida
proteins across the identified incomplete chromosome genome sequences available in the
NCBI database. The primary strain (complete chromosome from NCBI) was strain A449 [46].
The 4 sub-strains (incomplete chromosomes from NCBI) were strain: 01-B526, CBA100,
NBRC_13784 and pectinolytica_34mel.
Recombinant construct design
The 14 proteins were expressed in constructs based on conventional in silico analysis such as
prediction of signal peptides (SignalP-4.1) [47], transmembrane regions (TmHmm-2.0) [48],
non-classical secretion proteins (SecretomeP-2.) [49], functional and structural domains
(InterPro [39] and DomCut [50]) (Table 2). The rationale of expressing the protein in frag-
ments was due to: 1) enhanced probability of expressing the native protein structure, 2)
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Table 1. Rationale for protein selection.
PROTEIN ID RATIONALE
OF
SELECTION
FUNCTION LOCATION CONSERVATION (NCBI’s
incomplete chromosomes)
F L C InterPro server PSORTb server CELLO server % lc h/s M % sim. SD %
ASA_3320 x x extracellular enzyme activity unknown periplasmic 100 [4/4] 98 1
ASA_0826 x x virulent enzymatic activity extracellular extracellular 50 [2/4] 99 1
ASA_3455 x x x extracellular enzyme activity extracellular extracellular 50 [2/4] 99 1
ASA_3883 x x x iron sideophore receptor outer membrane outer membrane 100 [4/4] 98 2
ASA_2321 x x heme binding periplasmic periplasmic 100 [4/4] 98 2
ASA_0744 x x pathogenesis, membrane cytoplasmic periplasmic + cytoplasmic 100 [4/4] 97 2
ASA_1342 x x motility extracellular periplasmic 75 [3/4] 97 3
ASA_2532 x x motility unknown periplasmic 100 [4/4] 96 5
ASA_4042 x - periplasmic periplasmic 100 [4/4] 92 9
ASA_P5G035 x x adhesion, pilin assembly outer membrane extracellular + outer membrane 50 [2/4] 97 1
ASA_1675 x x x virulent enzymatic activity extracellular extracellular 50 [2/4] 98 1
ASA_3328 x x x haemoglobin/transferrin/lactoferrin receptor outer membrane outer membrane 100 [4/4] 98 3
ASA_3723 x x x collagenase extracellular outer membrane + cytoplasmic 100 [4/4] 99 2
ASA_4105 x x zinc metallopeptidase outer membrane outer membrane 100 [4/4] 98 2
Fourteen proteins of A. salmonicida subsp. salmonicida were selected as potential protective B-cell antigens. The column RATIONALE OF SELECTION
shows which criteria were responsible for the selection: functionality (F), location (L), conservation (C). E.g. protein ASA_2532 was selected due to its
predicted motility function domain by InterPro and its strong conservation. Besides being present in the primary strain A449 (complete chromosome), it was
represented in all NCBI’s incomplete chromosomes: number of homologs/number of strains (h/s). The % library coverage (% lc) of protein ASA_2532 is
100% meaning that this protein is 100% conserved across all sub-strains. Mean of % similarities to homologs (M % sim.) is 96% meaning this protein has an
average % identity of 96% to the homologs of the 4 sub-strains. SD is the standard deviation of % similarities to homologs.
doi:10.1371/journal.pone.0171944.t001
Table 2. Recombinant construct design, protein type and vaccine formulation.
Locus ID Expressed aa-region Predicted protein type Vaccine group Reference Removed
sequences
SP TM & IC
ASA_3320 24–640 endochitinase (chiB) VacA [46, 62,64] x
ASA_0826 2340–3195 RTX protein (asx)(only active site) VacA [46, 62,64]
ASA_3455 25–754 alpha-amylase (amyA) VacA [46] x
ASA_3883 25–680 outer membrane ferric siderophore receptor VacA x
ASA_2321 22–480 cytochrome c-552 (nrfA VacA x
ASA_0744 30–388 tolA protein (tolA) VacB x
ASA_1342 1–639 polar flagellar hook-length control protein (FliK) VacB [46]
ASA_2532 23–334 type IV pilus assembly protein TapV (tapV) VacB [65,66] x x
ASA_4042 19–402 hypothetical uncharacterized protein VacB x
ASA_P5G035 24–629 conjugal transfer mating pair stabilization protein (TraN) VacB x x
ASA_1675 310–1156 hemolysin-type calcium-binding protein (only active site) VacC [62]
ASA_3328 25–697 putative heme receptor (hupA) VacC [16, 46, 63] x
ASA_3723 210–915 microbial collagenase (only active site) VacC [46,62, 64] x
ASA_4105 35–468 M24/M37 family peptidase VacC x
All proteins are listed by their protein ID, expressed amino acid sequence (aa-region), predicted function, vaccine group, reference and construct design
showing if the sequence removed was a signal peptide (SP) or transmembrane (TM) and intracellular (IC) region.
doi:10.1371/journal.pone.0171944.t002
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expressing the protective part of the protein, 3) establishing a successful recombinant expres-
sion in E. coli. Predicted signal peptide or/and transmembrane and intracellular regions were
removed. Proteins bigger than 1000aa were split in N- and C-terminal fragments and only the
fragment comprising the predicted active functional site domains was expressed. The splitting
point of these fragments where decided based on structural domain predictor aiming at keep-
ing the native structure of each structural domain.
Protein expression
All recombinant protein constructs were expressed in E. coli by Creative Biomart (Shirley, NY,
USA).
Vaccine preparation
The 14 recombinant protein constructs were allocated in 3 groups as follows: VacA and VacB
(both 5 proteins) and vacC (4 proteins) (Table 2). A total of 25 μg of an individual protein was
prepared per fish in the vaccine mixture corresponding to a total of 100–125 μg of mixed pro-
teins per fish. The proteins were allowed to bind to Al(OH)3 by adding aluminium hydroxide
gel adjuvant Alhydrogel (Brenntag, Denmark) to each vial of mixed proteins. A volume of
100 μL Al(OH)3 was added per 160 μg protein and incubated at room temperature with end-
over-end rotation for 1 hour. The vials were then centrifuged at 216 G (Heraeus multifuge 3
L-R, Thermo Scientific, Denmark) at room temperature for 2 minutes. The supernatant was
removed and checked for the absence of proteins with NanoDrop 2000 (Thermo Scientific,
Denmark). The vials containing proteins bound to Al(OH)3 were washed twice with 0.9% ster-
ile NaCl—each time all vials were centrifuged at 216 G for 2 minutes at room temperature
whereafter the supernatant was removed. After the last wash an equal volume of Freund’s
Incomplete Adjuvant (FIA) (F5506, Sigma-Aldrich, Denmark) was added and the vials were
vigorously vortexed at room temperature for 1 hour. The vaccine control containing only
adjuvants was made accordingly without the protein constructs. The vaccines were stored at
4˚C until the further use.
Fish
Disinfected eyed rainbow trout eggs originating from Fousing Trout Farm, Jutland, Denmark
were translocated and hatched in a pathogen-free rearing facility at Bornholm Salmon Hatch-
ery (AquaBaltic, Denmark). Details of retaining the pathogen-free status have previously been
described [51]. Fish were immunized and then reared for 6 weeks (568 degree-days) in the sys-
tem containing recirculated municipal water at 13–14˚C in 700 L (1 m3) tanks and fed 1% bio-
mass per day with dry pellet feed (BioMar A/S, Denmark). Fish were transported to the fish
keeping facility at the University of Copenhagen, Frederiksberg, Denmark and acclimatized by
gradually raising the water temperature to 19˚C over the course of the week before the chal-
lenge (exposure to live AS) was performed. The study was approved under the license no.
2015-15-0201-00655 issued by the Animal Experiments Inspectorate, Ministry of Environ-
ment and Food, Denmark.
Vaccination
A total of 360 rainbow trout (average body weight of 30 g) were randomly divided into 6
groups of 60 fish (Table 3) and each group was further subdivided into duplicate tanks con-
taining 30 fish each. The fish were anaesthetized (75 mg L-1 MS222, Sigma-Aldrich, Denmark)
and i.p. injected with 0.1 mL of different formulations warmed up to fish body temperature
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(14˚C) prior the immunization. The different vaccine formulations included: 1) commercial
furunculosis vaccine Alpha Ject1 3000 (Pharmaq AS, Norway), 2) VacA, 3) VacB, 4) VacC
(the experimental subunit vaccines consisting of in silico predicted proteins), 5) adjuvant only
(the equal amount of Alhydrogel and FIA) and 6) saline.
Challenge experiment
At 7 weeks post-immunization (wpi) (690 degree-days) the 25 fish (now with an average body
weight of 40 g) in all the duplicate tanks were challenged with 5.4×108 CFU mL-1 AS strain
090710-1/23 by a challenge method using a multi-puncture device [37] producing 10 perfora-
tions in the tail fin with subsequent exposure to bacteria, for 90 seconds. Morbidity was moni-
tored every second hour during 3 weeks post-challenge (wpc). The moribund state was
defined as a complete loss of equilibrium, strong discoloration and development of skin hem-
orrhages. Moribund fish were immediately removed for euthanasia (300 mg L-1 MS222) and
recorded as mortalities. Swabs from head kidney of all freshly euthanized fish were plated onto
5% blood agar plates (SSI Diagnostica, Denmark) for bacteriological analysis. The confirma-
tion of AS was done according to Dalsgaard and Madsen [4] and the re-isolated bacteria from
the dead fish were confirmed as A. salmonicida subsp. salmonicida. The challenge trial was ter-
minated 3 wpc (24 days).
Sampling
Blood samples for ELISA (10 fish per group) were taken after vaccination (6 wpi) and after
challenge (3 wpc) (Table 3). Blood were collected by caudal vein puncture from euthanized
fish (300 mg L-1 MS222), allowed to clot at 4˚C overnight and serum was separated at 4˚C by
centrifugation (3000 G) for 10 minutes and stored at -80˚ C until further analysis.
ELISA
Enzyme-linked immunosorbent assay (ELISA) was performed according to previously estab-
lished protocol [52]. In brief, the 96-well microtiter plates (MaxiSorp™, Nunc, Denmark) were
coated overnight at 4˚C with either sonicated lysate of AS bacteria strain 090710-1/23 (protein
conc 5 μg mL-1) or individual recombinant proteins (conc 1 μg mL-1) and blocked with 2%
Bovine Serum Albumin (BSA, A4503, Sigma-Aldrich, Denmark) for 1 hour at room tempera-
ture. A total of 9 proteins (contained in VacB and VacC vaccines) showing best protection were
chosen for plate coating for ELISA. Working dilutions were selected considering preliminary
results. Dilutions 1:500 and 1:5000 were chosen for testing specific antibodies against sonicated
bacteria and dilutions 1:100, 1:1000 and 1:10 000 were chosen for testing specific antibodies
against individual proteins. All serum samples were diluted with assay diluent (0.1% BSA in
Table 3. Experimental setup presenting the different groups, sample size, mortality and relative percentage of survival (RPS).
Control Saline Control Adjuvant Alpha Ject® 3000 VacA VacB VacC
No. of immunized fish 60 60 60 60 60 60
No. of fish sampled for ELISA (7wpi) 10 10 10 10 10 10
No. of challenged fish 50 50 50 50 49* 48*
Mortality % 56 48 8 30 20 17
RPS - 14 86 46 64 70
No. of fish sampled for ELISA (3wpc) 10 10 10 10 10 10
* Fish, one and two, respectively, died after anaesthesia during the challenge infection.
doi:10.1371/journal.pone.0171944.t003
Subunit vaccines against furunculosis in rainbow trout
PLOS ONE | DOI:10.1371/journal.pone.0171944 February 9, 2017 5 / 15
wash buffer) and 100 μL of sample was added to each duplicate ELISA plate well and incubated
at 4˚C overnight. The plates were thereafter incubated with 100 μL mouse anti-salmonid Ig
(MCA2182 AbD Serotec, Germany, diluted 1:500) and 100 μL HRP-conjugated rabbit anti-
mouse IgG for 1 hour (STAR13B, AbD Serotec, Germany, diluted 1:500). The color reaction
was developed with 100 μL tetramethylbenzidine (TMB) PLUS substrate (BUF042A, AbD Sero-
tec, Germany) and stopped after 10 minutes by adding 100 μL 1N HCL. All ELISA plates
included 4 wells of pure assay diluent for the background absorbance measurement. The optical
density (OD) was measured at 450 nm in an Epoch spectrophotometer (BioTek, USA) in dupli-
cate wells.
Statistical analysis
The relative percentage of survival (RPS) was calculated as proposed by Amend [53]: RPS = [1-
(% mortality in vaccinated fish / % mortality in control fish)] × 100. All statistical tests were
performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, USA, www.
graphpad.com) and P-values< 0.05 were considered statistically significant. Mortality data
was analyzed using Kaplan-Meier survival analysis and log-rank test. Duplicate groups were
pooled after survival curve comparison showed no significant difference in mortalities. ELISA
results were compared using one-way ANOVA followed by Tukey’s Multiple Comparison
post hoc test. Fish from duplicate tanks were pooled after t-test had confirmed no significant
difference between them. Correlation was calculated as Pearson correlation coefficient (r).
Results
Challenge experiment
All fish were challenged at 7 wpi by multi-puncture of the upper caudal fin and local exposure
to a known number of AS. The mortality post-challenge (pc) is shown in Fig 1. Mortality
started at day 3 pc in all fish groups and subsided by day 6 pc. Thereafter minor mortality still
occurred until day 15 pc. The highest cumulative mortality was recorded in the saline control
group (56%) followed by the adjuvant only control group (48%). Mortalities in the experimen-
tal subunit vaccine groups VacA (30%, RPS 46), VacB (20%, RPS 64) and VacC (17%, RPS 70)
were significantly lower than in the saline control group. The lowest cumulative mortality, but
Fig 1. The cumulative mortality in rainbow trout experimental groups (replicates pooled) following infection
challenge with A. salmonicida. Asterisks (*) represent p values between groups (*p<0.05, **p< 0.01, ***p< 0.001).
doi:10.1371/journal.pone.0171944.g001
Subunit vaccines against furunculosis in rainbow trout
PLOS ONE | DOI:10.1371/journal.pone.0171944 February 9, 2017 6 / 15
not significantly different form VacB and VacC groups, occurred in the group immunized
with the commercial vaccine Alpha Ject1 3000 (8%, RPS 86).
ELISA
ELISA analyses were conducted to measure the antibody response towards sonicated bacteria
and individual recombinant proteins in different groups of immunized fish. Here we highlight
only significant differences (p<0.05) in antibody response that occurred when comparing the
immunized fish groups (Alpha Ject1 3000, VacA, VacB, VacC) with the control fish groups
(saline control and adjuvant control).
Antibodies against sonicated AS. Antibody levels against sonicated bacteria in sera
(diluted 1:500) from fish vaccinated with Alpha Ject1 3000 were significantly higher compared
to all other groups at 7 wpi and 3 wpc (Fig 2). A slight but non-significant antibody increase
against sonicated bacteria was seen in the groups immunized with the subunit vaccines when
compared to the control groups.
Antibodies against 9 recombinant proteins. The fish immunized with the Alpha Ject1
3000 had significantly higher antibody response against all 9 recombinant proteins when com-
pared to the control groups at 7 wpi and 3 wpc. Fish immunized with experimental vaccines
(recombinant proteins) showed diverse antibody responses to these proteins (Figs 3 and 4).
Antibodies against proteins in VacB vaccine. Significantly higher antibody levels were
found in fish immunized with experimental vaccine VacB containing recombinant proteins
ASA_0744, ASA_1342, ASA_2532, ASA_4042, ASA_P5G035 compared to the saline injected
control group. This group showed significantly higher serum antibody levels (diluted 1:100)
against proteins ASA_1342, ASA_2532, ASA_4042, ASA_ P5G035 at 7 wpi (Fig 3A) and against
ASA_P5G035 at 3 wpc (Fig 3B). In addition, fish immunized with experimental vaccine VacA
(ASA_3320, ASA_0826, ASA_3455, ASA_3883, ASA_2321) had significantly higher antibody
levels in sera (1:100) against few vaccine VacB proteins: ASA_1342 and ASA_P5G035 after
immunization (7 wpi) (Fig 3A) and ASA_0744 after challenge (3 wpc) (Fig 3B).
Antibodies against proteins in VacC vaccine. Fish immunized with peptides of experi-
mental vaccine VacC (ASA_1675, ASA_3328, ASA_3723, ASA_4105) had significantly ele-
vated antibody levels in sera (diluted 1:100) against ASA_1675 at both 7 wpi (Fig 4A) and 3
wpc (Fig 4B) when compared to the control groups.
Fig 2. Levels of A. salmonicida-specific antibodies in serum measured by ELISA at 7 weeks post-
immunization (wpi) and 3 weeks post- challenge (wpc). Sera (diluted 1:500) were analyzed from 10 fish
per group (5 fish per duplicate tank). Asterisks (*) represent p values (*p<0.05, **p< 0.01, ***p< 0.001)
compared to saline control group.
doi:10.1371/journal.pone.0171944.g002
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Fig 3. Levels of antibodies in serum of fish against individual VacB vaccine proteins. Sera (diluted 1:100) was measured by ELISA from 10
fish per group (5 fish per duplicate tank) at 7 weeks post-immunization (wpi) (a) and at 3 weeks post-challenge (wpc) (b). Asterisks (*) represent p
values (*p<0.05, **p< 0.01, ***p< 0.001) when compared to saline control group.
doi:10.1371/journal.pone.0171944.g003
Fig 4. Levels of antibodies in serum of fish against individual VacC vaccine proteins. Sera (diluted 1:100) was measured by ELISA from 10
fish per group (5 fish per duplicate tank) at 7 weeks post-immunization (wpi) (a) and at 3 weeks post-challenge (wpc) (b). Asterisks (*) represent p
values (* = P<0.05, ** = P< 0.01, *** = P< 0.001) when compared to saline control group.
doi:10.1371/journal.pone.0171944.g004
Subunit vaccines against furunculosis in rainbow trout
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Correlation between antibody levels and survival
The correlation between serum antibody (diluted 1:100) levels against recombinant proteins at
7 wpi and the survival at day 24 pc was calculated as Pearson correlation coefficient (r). A sig-
nificant (p<0.05) positive correlation was found for antibody reactivity against VacB proteins
ASA_2532 (Pearson r = 0.86; R2 = 0.73), ASA_P5G035 (Pearson r = 0.81; R2 = 0.66) and VacC
protein ASA_1675 (Pearson r = 0.81; R2 = 0.67) (Fig 5).
Discussion
This study utilized recombinant proteins encoded by the genome of A. salmonicida subsp. sal-
monicida A449 for immunization against furunculosis. The in silico approach also known as
reverse vaccinology [54] has been used to identify vaccine candidates for bacterial fish diseases
in few studies previously [55–57] but to the best of our knowledge—this is the first time it has
been applied for A. salmonicida subsp. salmonicida. The 14 antigens selected for this study
were presumed to be associated with hemoglobin binding, adhesion, iron-acquisition, calcium
and siderophore binding, motility, enzymatic and collagenase activity and possess the right
characteristics to be surface exposed proteins. The protective properties of these 14 recombi-
nant protein antigens were tested by in vivo challenge experiment. The experimental setup
included 3 groups of fish immunized with protein antigens, one group immunized with a com-
mercial vaccine Alpha Ject1 3000 and 2 control groups injected with either saline or adjuvant
only. Antigens administered in experimental subunit vaccines induced protection in the
immunized fish. Thus, all the groups of fish immunized with experimental vaccines experi-
enced significantly lower mortalities compared to the saline control group or the group
injected with adjuvant (Fig 1). The fish vaccinated with Alpha Ject1 3000 had significantly
higher antibody levels against sonicated bacteria when compared to all the other groups (Fig
2) and performed best (mortality 8%) throughout the challenge study but not significantly bet-
ter compared to the vaccine groups VacB and VacC (20% and 17% mortality, respectively).
The experimental vaccine group VacA exhibited the highest mortality (30%) among the
groups immunized with in silico predicted antigens but the mortality was still significantly
lower compared to the control fish injected with saline (56%).
The ELISA analysis measuring antibody response against the individual proteins showed
that fish vaccinated with the commercial vaccine had significantly higher antibody levels
Fig 5. Correlation between mean antibody (diluted 1:100) levels for individual proteins at 7 weeks post-immunization (wpi) and
survival in different experimental groups at 24 days post-challenge (dpc). Antibody levels were measured from 10 fish per group (5
fish per duplicate tank) by ELISA one day before challenge.
doi:10.1371/journal.pone.0171944.g005
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against all individual proteins included in experimental vaccines VacB and VacC when com-
pared to the saline control group. The fish immunized with the experimental vaccine VacC
reacted with elevated antibody levels against ASA_1675—a protein that was included in the
VacC vaccine formulation. Antibody reactivity against ASA_1675 was significantly higher
both after the immunization and challenge when compared to the control groups and other
experimental vaccine groups (Fig 4). This suggests that ASA_1675 is highly immunogenic and
may play a role in protection considering VacC vaccine fish exhibited the lowest mortality
among the experimental vaccine groups and that the antibody levels against ASA-1675 mea-
sured before challenge were positively correlated with the fish survival (Fig 5). However as the
experimental vaccines consisted of different proteins, their individual contribution to vaccine
induced protection is uncertain and the role of ASA_1675 should be assessed in further stud-
ies. The protein ASA_1675 is a hemolysin-type calcium binding repeat-containing protein
belonging to a family of putative RTX (repeats-in-toxin) proteins involved in various biological
functions like S-layer formation, adhesion, pore formation, hemolysis, cytolysis etc. [58]. The
RTX family proteins are secreted by the type I secretion system (TISS) of Gram negative bacte-
ria and have shown to be important virulence factors in various bacteria [58, 59] including
Aeromonas hydrophila ATCC 7966T [60] and Vibrio anguillarum [61]. The secretion of the
protein in AS seems to occur only in vivo [62]. Other proteins in VacC vaccine formation men-
tioned previously in relation to AS virulence [46] are ASA_3328 and ASA_3723. The
ASA_3328 is a putative heme receptor (hupA) involved in heme utilization [63] and has
observed exclusively up-regulated under in vivo and in iron-restricted conditions in vitro [16].
The ASA_3723 is a microbial collagenase orthologue to a putative virulence determinant
AHA_0517 in A. hydrophila [60] and among one of the most secreted proteins in the superna-
tant of virulent AS [62, 64]. The ASA_4105 is a M24/M37 family zinc metallopeptidase and
has not been previously mentioned as potential virulent factor of AS but was chosen in VacB
vaccine due to its outer membrane location and the conservation across A. salmonicida sub-
strains.
The fish that were immunized with the VacB vaccine exhibited significantly higher anti-
body levels against 4 out of 5 proteins they were immunized with (Fig 4) but the antibody
reactivity against these proteins was not as distinguished as the antibody response against
ASA_1675 in fish vaccinated with VacC vaccine. The VacB proteins inducing higher antibody
response in fish vaccinated with VacB vaccine included ASA_1342, ASA_2532, ASA_4042
and ASA_P5G035. ASA_1342 is a the polar flagella hook-length control protein (FliK) that has
previously been mentioned as potential virulent factor of AS having homologues to flagella
proteins in A. hydrophila [46]. ASA_2532 is a type IV pilus assembly protein (TapV) shown to
contribute to virulence of AS by being engaged in bacterial adhesion [65] and is homologues
to FimV in Pseudomonas aeruginosa [66] and similar to pilus assembly proteins in other patho-
genic bacteria [67]. The other 3 proteins in VacB vaccine: the hypothetical uncharacterized pro-
tein ASA_4042, the conjugal transfer mating pair stabilization protein (TraN) ASA_P5G035
and the tolA protein ASA_0744 have not been previously implicated in AS virulence and were
chosen for this study on the bases of conservation, functionality and cellular location. Further-
more, the tolA protein in E. coli has shown to be a major virulence factor [68]. The fish in VacB
vaccine group experienced a mortality of 20% suggesting the protective nature (at least some) of
the VacB proteins. In addition, the antibody reactivity against ASA_2532 and ASA_P5G035
before the challenge was positively correlated to the survival (Fig 5). Unexpectedly, the fish
immunized with VacA vaccine developed significantly elevated antibody levels against few pro-
teins in VacB vaccine—ASA_1342, ASA_P5G035 (after immunization) and ASA_0744 (after
challenge) suggesting some unspecific binding of antibodies.
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The VacA subunit vaccine included two secreted enzymes: the alpha-amylase (AmyA)
ASA_3455 and the endochitinase (chiB) ASA_3320. Both have previously been mentioned as
potential virulence factors of AS by Reith [46]. In addition, ASA_3320 has been found abun-
dantly present in supernatant of virulent AS [62, 64]. Another previously mentioned putative
virulence factor included in the vaccine was ASA_0826—the RTX protein (asx) that belongs to
the RTX family associated with virulence in numerous Gram-negative bacteria [58, 69].
ASA_0826 is an orthologue to a putative virulence factor AHA_3491 in A. hydrophila [46, 60]
and have been found abundantly present in AS supernatant [62–64]. ASA_3883 –a TonB
dependent ferric siderophore receptor—is an outer membrane protein and was chosen as vac-
cine candidate based on its conservation and functionality. In addition, siderophore receptors
have been used as potential vaccine candidates against E. coli in mammalian studies [70–72].
ASA_2321 –a cytochrome C-552 (nrfA) was selected due to functionality and conservation
among sub-strains. VacA vaccine proteins were not included in the ELISA analysis due to the
lower protective effect and the data on antibody response is not available.
Fish vaccinated with the commercial vaccine was expected to develop a high antibody
response against both sonicated bacteria and individual proteins as they were injected with
whole cell bacterin, exposing them to a high concentration of a wide array of antigens com-
pared to the fish immunized only with 100–125 μg of potentially immunogenic proteins. The
latter fish exhibited a lower antibody response compared to the fish vaccinated with the com-
mercial vaccine but still had high survival. This could indicate that the antibody response is
not the only protective factor and that the cellular immunity could be involved in protection.
The role of these antigens in vaccine protection should be further elucidated in future studies
where proteins are evaluated individually in immunization assays.
Some of the candidate proteins have been previously mentioned as potential virulence fac-
tors and protective antigens [16, 46, 62, 64, 65] but the in vivo protective potential of those
antigens has not been assessed before. This study showed that immunization with previously
proposed and few new candidate proteins increased the survival of fish and the survival can be
related to the antibody producing protective properties that these proteins may have.
Future perspectives
Recombinant AS 449 proteins, when applied in experimental vaccines, induce protection
against furunculosis and could therefore be considered as vaccine candidates. However the
protective input of each antigen needs to be evaluated by single protein immunization to con-
firm their individual contribution to protection. The relation between antigen concentration
and protection should be determined and suitable adjuvants must be selected.
The side-effects in fish immunized with the subunit vaccines adjuvanted with a mixture of
Al(OH)3 and FIA were not assessed in this study. However, side-effects studies are crucial
when testing new vaccine formulations. It is therefore necessary to develop and evaluate the
side-effects of suitable adjuvants in future studies.
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